



LANXESS – Credit Suisse Canada Roadshow

Michael Pontzen, CFO 21 September 2021

Safe harbor statement



The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Agenda

1 LANXESS transformation journey continues

2 Financial and business details Q2 2021

3 Back-up

Five of the most striking reasons to invest




1. Embark on an exciting transformation journey to high margin specialty chemicals businesses

2. Unique specialty chemicals portfolio with leading market positions

3. Proven resilient business model – with many growth options


4. Forerunner in sustainability – awarded by leading rating agencies

5. Energizing chemistry – committed management team embedded in performance oriented corporate culture



LANXESS: Strong transformation via active portfolio management





5

We promised – we delivered: Two perfectly fitting acquisitions in Consumer Protection





Emerald Kalama Chemicals

- Strategic expansion into attractive Flavors & Fragrances end markets
- Strong secular growth markets above GDP
- Highly synergistic, both cost and top line synergies
- Straight forward integration into LANXESS




IFF Microbial Control

- Building one of the key players in biocides
- Complementary product portfolio in biocides & regional coverage
- Attractive synergy and cash flow profile
- Smooth integration and matching cultures

€~80 m	22-25%	€~85 m	>20%			
EBITDA pre*	EBITDA pre margin	EBITDA pre**	EBITDA pre margin			
Attractive financial profile: High margins, asset light, strong cash conversion						

Recent acquisitions lift Consumer Protection to the next level






- Consumer Protection grows from smallest to largest segment
- Specialty chemicals businesses drive group margin improvement
- Higher cash conversion due to asset light character of the businesses
- Growing resilience due to increased exposure to non-cyclical end markets

LANXESS financial profile improves as Consumer Protection exposure broadens


Strong portfolio of attractive businesses





Proven resilient business model – platform for further growth





Our exciting journey to high margin specialty chemicals transformation continues



Organic	; growth	Inorganic growth
Strong secular growth in Consumer Protection	Attractive brownfield investments	Emerald Kalama Chemical
Digital growth projects e.g. Chemondis	Attractive greenfield investments, e.g. battery chemistry	THESEO Microbial solutions* to be continued!

Forerunner in sustainability – awarded by leading rating agencies





Energizing chemistry – committed management team embedded in performance oriented corporate culture





- Management team with proven track record and industry experience
- Combined ~80 years of LANXESS experience and ~120 years in the chemical industry
- Performance culture and lean corporate structure enable fast decision-making
- Management with skin in the game and incentivized by absolute sustainability targets



1 LANXESS transformation journey continues

2 Financial and business details Q2 2021

3 Back-up

Q2 2021: Back on pre-COVID level



Highlights

- Volumes back on pre-Covid level
- Strong recovery especially in Engineering Materials and Specialty Additives
- Significant EBITDA pre increase to €277 m (+24%), margin at 15.1%, despite further raw material and energy price increase and intensive logistic constraints
- Divestment of organic leather business closed
- Strengthening of R&D capacities in APAC: New Application Development Center in Shanghai
- Emerald Kalama acquisition closed (3rd August)





Strong volume growth, but higher costs and FX burden

[€ m]*	Q2/2020	Q2/2021	Δ	1H 2020	1H 2021	Δ
Sales	1.436	1.831	28%	3.140	3.524	12%
EBITDA pre	224	277	24%	469	519	11%
Margin	15,6%	15,1%		14,9%	14,7%	
CAPEX	88	92	5%	162	162	0%

	Volume +22%		
Q2 Sales		otal -	⊦28 %

15

- Strong sales growth driven by volumes and price increases mitigated by adverse FX effect
- Significant volume growth across all segments
- EBITDA pre significantly above previous year level due to ongoing volume growth, despite higher energy and logistic costs as well as adverse FX effect



Advanced Intermediates: Benefitting from strong demand



Like-for-like above previous year level

[€ m]*	Q2/2020	Q2/2021	Δ	1H 2020	1H 2021	Δ
Sales	430	505	17%	913	994	9%
EBITDA pre	103	96	-7%	185	173	-6%
Margin	24,0%	19,0%		20,3%	17,4%	
CAPEX	28	31	11%	51	52	2%


Price Volume +10% +11%		-
TC Q2 Sales vs. PY	otal -	⊦17 %

- Sales increase driven by significantly higher volumes and prices in both BUs, partly offset by negative FX effect
- EBITDA pre and margin impacted by higher energy and freight costs
- Considering €10 m tailwind in Q2 2020, EBITDA pre already now exceeds PY level

* New reporting structure as of Q1 2021: "Antioxidants and Accelerators" (AXX) business shift from BU AII to BU RCH (segment "Specialty Additives");

2020 figures restated

16



Specialty Additives: Strong volume growth



Recovery in several key industries

[€ m]*	Q2/2020	Q2/2021	Δ	1H 2020	1H 2021	Δ
Sales	442	568	29%	1.016	1.085	7%
EBITDA pre	60	89	48%	151	163	8%
Margin	13,6%	15,7%		14,9%	15,0%	
CAPEX	20	24	20%	40	40	0%

	Volume +30%		Portfolio 0%
Q2 Sales		tal -	⊦29 %

- Sales increase due to rising volumes and prices across all BUs
- Rising volumes in all BUs, strong demand especially in BU PLA and BU RCH
- EBITDA pre improving but held back by soaring freight costs and adverse FX effect; margin diluted by shift of AXX business (~2% p.p.)

* New reporting structure as of Q1 2021: Business Line "Antioxidants and Accelerators" (AXX) shift from BU All to BU RCH (segment "Specialty Additives"); 2020 figures restated



Consumer Protection: Delivering against high comparable base



Attractive bolt-on acquisitions contribute

[€ m]	Q2/2020	Q2/2021	Δ	1H 2020	1H 2021	Δ
Sales	301	314	4%	580	604	4%
EBITDA pre	68	65	-4%	135	134	-1%
Margin	22,6%	20,7%		23,3%	22,2%	
CAPEX	12	13	8%	22	26	18%

Price	Volume	FX	Portfolio			
-1%	+5%	-2%	+2 %			
Total +4%						
Q2 Sales	vs. PY					

- Sales driven by strong volume increase in BU MPP
- New long-term contract at BU SGO with favorable net price-volume effect
- EBITDA pre on strong previous year's level which was overstated by pre-buying at BU SGO, margin slightly lower due to logistic costs



Engineering Materials: Recovery in automotive drives strong earnings



Earnings more than doubled

[€ m]	Q2/2020	Q2/2021	Δ	1H 2020	1H 2021	Δ
Sales	244	424	74%	591	801	36%
EBITDA pre	28	68	143%	77	127	65%
Margin	11,5%	16,0%		13,0%	15,9%	
CAPEX	12	12	0%	20	22	10%

	Volume +50%		
Q2 Sales		otal +	74%

- Sales boost based on strong demand from auto industry, partly offset by negative FX
- Volumes and prices significantly increased in BU HPM; BU URE also with positive development
- EBITDA pre and margin rise on improved volumes and higher prices, despite burden from supplier's force majeure, higher energy and freight costs as well as FX

P&L Q2: Recovery kicks in




[€ m]*	Q2/2020		Q2/2021		yoy in %
Sales	1.436	(100%)	1.831	(100%)	28%
Cost of sales	-1.042	(-73%)	-1.356	(-74%)	30%
Selling	-194	(-14%)	-225	(-12%)	16%
G&A	-64	(-4%)	-70	(-4%)	9%
R&D	-28	(-2%)	-29	(-2%)	4%
EBIT	61	(4%)	125	(7%)	>100%
Net Income	798	(56%)	100	(5%)	-87%
EPS pre	0,86		1,38		60%
EBITDA	198	(14%)	247	(13%)	25%
thereof except.	-26	(-2%)	-30	(-2%)	15%
EBITDA pre except.	224	(15,6%)	277	(15,1%)	24%

- Cost of sales inflated by higher raw material and energy costs
- Increase in selling expenses reflects higher logistic and storage costs
- Strong earnings reflect recovering demand despite higher energy and logistic prices as well as negative FX development
- Net income in previous year includes proceeds from CURRENTA divestment

* From continuing operations

Q2 2021: Strong recovery supported by Specialty Additives and Engineering Materials






* Total group sales including reconciliation

Q2 2021: Strong operational development in all areas





* Currency and portfolio adjusted

Operating cash flow burdened by working capital increase

[€ m]	Q2/2020	Q2/2021	Δ
Operating cash flow*	52	-10	-62
thereof changes in working capital	56	-165	-221
Investing cash flow*	88	182	94
thereof capex	-88	-92	-4
thereof payments for acquisitions / proceeds from divestments	734	12	-722
thereof net invest in money markets	-710	260	970



- Operating cash flow impacted by
 - Significant increase in inventories due to volume uptick and inflated raw material prices
 - Higher receivables based on increased sales
- Portfolio management:
 - Previous year investing cash flow reflects divestment of CURRENTA
 - Net amount in 2021 includes purchase price for Theseo netted against divestment of organic leather business

Strong balance sheet



[€ m]	31.12.2020	30.06.2021
Total assets	8.880	9.149
Equity	2.999	3.352
Equity ratio	34%	37%
Net financial debt ¹	1.012	1.309
Cash, cash equiv., short term money market inv.	1.794	1.502
Pension provisions	1.205	990
Net working capital	1.134	1.462
DSI (in days) ²	64	64
DSO (in days) ³	45	47

- Equity reflects positive net income, effects in pension provision and FX
- Ongoing strong liquidity increase in net financial debt partly driven by dividend payment (€86 m), which was paid in Q3 last year
- Lower pension provisions reflect interest rate increase
- Strong increase in working capital due to higher inventories driven by inflated raw material prices as well as higher receivables based on increased sales

¹ Including cash, cash equivalents, short-term money market investments

² Days sales of inventory calculated from quarterly sales ³ Days of sales outstanding calculated from quarterly sales

24

LANXESS has once again improved its sustainability ratings



AAA A A BBB B B CCC AUG '18 AUG '19 OCT '20 JUN '21

MSCI ESG rating upgrade to AA

- LANXESS way above average in Corporate Governance
- Convincing climate strategy and continuous improvement in Chemical Safety
- Upgrade driven by water stress risk assessment



 EcoVadis covering more than 75,000 companies globally with sustainability ratings


EcoVadis rating upgrade to Platinum

- LANXESS perceived as strong performer in labor & human rights
- Upgraded due to improved performance in environmental dimension

Leading ESG rating providers honor our performance

LANXESS guidance raised – Emerald Kalama Chemical contribution included





Current view on economy

- In general, ongoing recovery expected:
 - Growing demand especially in automotive, chemical industry and construction
 - Aviation and oil & gas modestly to gradually improving
- Ongoing strong development for Consumer Protection markets
- Course of pandemic and global logistic constraints remain risk factors

LANXESS outlook

- FY 2021 EBITDA pre expected €1,000 1,050 m
 - Strong development of underlying business
 - Emerald Kalama Chemical contribution ~€35 m



1 LANXESS transformation journey continues

2 Financial and business details Q2 2021

3 Back-up



Housekeeping items 2021



Capex 2021 Operational D&A 2021 **Reconciliation 2021** Underlying tax rate Exceptionals 2021 FX sensitivity Effects from EKC acquisition

~€450-500 m (incl. EKC)

~€450 m (excl. EKC)

~€150-160 m including remnant costs and re-occurring expenses
~28%


€120-150 m based on current initiatives (including ~€15m OTCs* Emerald Kalama Chemical)

One cent change of USD/EUR resulting in **~€7 m** EBITDA pre impact before hedging

Further details will be provided in Q3 presentation

Together, LANXESS and IFF MC complement their business activities in microbial control solutions






Combined, IFF MC & LANXESS as global player with broad portfolio & diverse application coverage


Acquisition of IFF Microbial Control (MC) Business: Attractive strategic characteristics





Flavor & Fragrance products combined in new business unit within the Consumer Protection segment





31

Emerald Kalama Chemical offers a 100% complementary fit to LANXESS





Consumer Specialties (~75%)

Animal Health

- Preservatives for feed silage
- Animal feed additives substituting anti-biotics

Growth > GDP

Food & Beverage

 High quality preservatives for food and beverages

Growth ~ GDP



Flavours & Fragrances

 ~30 aroma ingredients for food, home & personal care products

Growth > GDP

Home & Personal Care

 Nature identical high purity preservatives for cleaning applications & cosmetics

Growth ~ GDP



Industrial Specialties (~25%)

CASE* & Polymers


- Phthalate-free plasticizers for:
 - Construction materials: e.g. flooring, sealants
 - Adhesives: substitution for mechanical fastening
 - Coatings and paper-based packaging



Growth > GDP


IFF MC: strong financials and asset light model





A complementary fit – strong levers for LANXESS to build on IFF MC product platform & market access





IFF MC: Targeting €30m synergies, thereof €25m by 2024




Top line synergies: ~ €10m

- Complementary geographies and customers
- Cross selling potential
- New applications: energy market and hygiene


Cost synergies: ~ €20m

- Streamlining of sales office infrastructure
- Optimization of supply chain and distribution model
- Sourcing synergies
- Manufacturing excellence



IFF MC: Attractive deal metrics - closing expected in Q2 2022






Acquisition will be debt financed within investment grade rating

IFF MC: Global market presence in key microbial control application segments





Combination of IFF MC and LANXESS takes us to the next level

Creating one of the leading players in microbial control


Attractive synergy level with high margin and strong cash flow

Smooth integration and matching cultures

Strategic fit strengthening Consumer Protection focus


LANXESS closes acquisition of Emerald Kalama Chemical





Acquisition of Emerald Kalama Chemical: A tailor-made strategic fit!






* cash conversion = EBITDApre – CAPEX / EBITDApre (mid-term)

40 ** based on Benzoic acid & Benzaldehyde

The combined product portfolio brings consumer protection to everyone's daily life




Emerald Kalama's products complement LANXESS' Consumer Protection portfolio perfectly




** Additives: e.g. Active Ingredients & Intermediates (Pharma): Processing Agents (Food)

Emerald Kalama Chemical acquisition: Synergies, OTCs and Capex step in earlier than expected






LANXESS closes divestment of organic leather business LANXESS



* TFL Ledertechnik GmbH is a portfolio company of Black Diamond Capital Management, L.L.C. ** Subject to the approval of the relevant authorities


EU market for battery chemicals to grow to over EUR 10 billion by 2025





LANXESS offers key products for Li-Ion batteries





45

Battery housing

 PA/PBT compounds for components of the e-powertrain (BU HPM)

Electrolyte

- Key materials (Hydrofluoric acid, phosphorus chemicals) for electrolyte salt (LiPF₆) (BU AII/BU PLA)
- Flame retardants (BU PLA)

Cathode & Anode

- Iron oxide as precursor for cathode active materials (BU IPG)
- Ion-exchange resins for refining battery grade cobalt, nickel and lithium (BU LPT)
- Lithium chemicals from tail-brine (BU PLA)*


LANXESS starts electrolyte production for Li-Ion batteries in cooperation with market leader TINCI



Partnership with TINCI

- TINCI (Chinese Guangzhou Tinci Materials): a leading manufacturer for battery materials and the largest electrolyte producer worldwide
- Saltigo starts electrolyte production for TINCI in its hightech plant in Leverkusen (Germany) early 2022

TINCI with leading position in fragmented electrolyte market*



Local raw material supply is key for cell manufacturers and OEMs

On track to climate neutrality in 2040: Nitrous oxide reduction in Antwerp





Milestone in our climate strategy


- Nitrous oxide is generated during caprolactam production
- Investment of approx. EUR 10 million

Plant significantly reduces emissions: 150 kt CO₂e / year less

Second plant planned for 2023 Impact: 300 kt CO₂e / year less

Key Figures: Back on pre COVID level





H1 2021: Strong earnings



[€ m]	H1 2020		H1 2021		yoy in %
Sales	3.140	(100%)	3.524	(100%)	12%
Cost of sales	-2.311	(-74%)	-2.622	(-74%)	13%
Selling	-396	(-13%)	-433	(-12%)	9%
G&A	-138	(-4%)	-143	(-4%)	4%
R&D	-54	(-2%)	-56	(-2%)	4%
EBIT	165	(5%)	223	(6%)	35%
Net Income	862	(27%)	164	(5%)	-81%
EPS pre*	2,03		2,55		26%
EBITDA	417	(13%)	462	(13%)	11%
thereof except.	-52	(-2%)	-57	(-2%)	10%
EBITDA pre except.	469	(14,9%)	519	(14,7%)	11%

- Increase in selling expenses reflects higher logistic costs and negative FX effect
- Strong earnings reflect recovering demand despite higher energy and logistic prices as well as negative FX development
- Net income in previous year includes proceeds from CURRENTA divestment

Operating cash flow H1 2021 burdened by working capital increase




[€ m]	H1 2020	H1 2021	Δ
Operating cash flow*	165	23	-142
thereof changes in working capital	-125	-311	-186
Investing cash flow*	13	712	699
thereof capex	-162	-162	0
thereof payments for acquisitions / proceeds from divestments	787	4	-783
thereof net invest in money markets	-769	864	1.633

- Operating cash flow impacted by
 - Significant increase in inventories due to volume uptick and inflated raw material prices
 - Higher receivables based on increased sales
- Portfolio management:
 - Previous year investing cash flow reflects divestment of CURRENTA stake and chrome business
 - Net amount in 2021 includes purchase price for Theseo and Intace netted against divestment of organic leather business

^{*} Applies to continuing operations

H1 2021: Strong recovery supported by Specialty Additives and Engineering Materials






* Total group sales including reconciliation



Energizing Chemistry



* Currency and portfolio adjusted

Exceptional items (on EBIT) below previous year level



[€ m]	Q2/ Excep.	2020 Thereof D&A	Q2/ Excep.	2021 Thereof D&A	H1 Excep.	2020 Thereof D&A	H1 Excep.	2021 Thereof D&A	Comments
Strategic Realignment & Restructuring	25	18	5	1	41	18	7	1	incl. adjustment of production network
M&A, Digitalization (incl. Chemondis) and Others	13	1	21	0	17	0	39	0	incl. CUR, organic leather, membrane divestments, Emerald Kalama, Theseo, Intace acquistions
Strategic IT projects	7	0	6	1	13	1	13	1	incl. SAP Hana Project
Total	45	19	32	2	71	19	59	2	


First senior EUR benchmark bond issued to finance the acquisition



Long-term financing strategy


- Diversified financing sources
 - Bonds & private placements
 - Undrawn sustainable revolving credit facility
- Bridge financing for acquisition of IFF Microbial Control in place
- Balanced maturity profile will be maintained

Balanced maturity profile



Upcoming virtual events 2021 -Proactive capital market communication





Contact details Investor Relations





Oliver Stratmann Head of Treasury & Investor Relations

Tel.: +49 221 8885 9611 Fax.: +49 221 8885 5400 Mobile: +49 175 304 9611 Email: Oliver.Stratmann@lanxess.com



Mirjam Reetz Retail Investors

Tel.: +49 221 8885 1272 Mobile: +49 151 7461 3158 Email: Mirjam.Reetz@lanxess.com



André Simon Head of Investor Relations

Tel.: +49 221 8885 3494 Mobile: +49 175 302 3494 Email: Andre.Simon@lanxess.com



Eva Frerker Institutional Investors / Analysts

Tel.: +49 221 8885 5249 Mobile: +49 151 7461 2969 Email: Eva.Frerker@lanxess.com



Lisa Häckel Investor Relations Assistent

Tel.: +49 221 8885 9834 Mobile: +49 151 7461 4637 Email: Lisa.Haeckel@lanxess.com



Anja K. Siehler Institutional Investors / Analysts

Tel.: +49 221 8885 1035 Mobile: +49 151 74612789 Email: anja.siehler@lanxess.com



Abbreviations





Advanced Intermediates

All	Advanced Industrial Intermediates
IPG	Inorganic Pigments



Consumer Protection

F&F	Flavors & Fragrances
LPT	Liquid Purification Technologies
MPP	Material Protection Products
SGO	Saltigo



Specialty Additives

LAB	Lubricant Additives Business
PLA	Polymer Additives
RCH	Rhein Chemie



Engineering Materials

HPM	High Performance Materials
URE	Urethane Systems

LANXESS Energizing Chemistry